PrimeRFP SCOUT · Federal Contract Recompete Brief

36C24523P0029 — BLIND DRUG SAMPLES

BLIND DRUG SAMPLES is a federal NONE award for Department of Veterans Affairs (VA) held by ELSOHLY LABORATORIES INC. Estimated value $152K ($33K obligated). Current period of performance ends Oct 14, 2027. Last award drew 1 bidder. Place of performance: WASHINGTON DC.

$152K
Estimated Value
$33K
Obligated
Oct 14, 2027
PoP End / Expires
1
Bidders (last award)
ELSOHLY LABORATORIES INC
Incumbent

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

ELSOHLY LABORATORIES INC holds $91K across 1 federal awards, concentrated at Department of Veterans Affairs (VA). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Oct 14, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number36C24523P0029
AgencyDepartment of Veterans Affairs (VA)
IncumbentELSOHLY LABORATORIES INC
CAGE0Y0R0
UEISQB7R3XYCW35
NAICS541380

No full NAICS 541380 intel page yet. Browse NAICS intelligence

PSCQ301
Place of performanceWASHINGTON DC
Pricing typeFirm Fixed Price
Extent competedNot Competed Under SAP
PoP startOct 15, 2022
PoP end (current)Oct 14, 2027
Obligated$33K
Current value$118K
Potential value$152K

Recompete timing

Public
Expiring in 420 days

Current PoP ends Oct 14, 2027 (420 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Watch this contract — one email →

Incumbent footprint

Public record

ELSOHLY LABORATORIES INC$91K obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)
Department of Veterans Affairs (VA)$91K · 100% of firm total

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for 36C24523P0029
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Explore more pipelines →

Browse every live recompete landscape — by vehicle, agency, and set-aside.

Frequently asked questions

What is contract 36C24523P0029?

36C24523P0029 (BLIND DRUG SAMPLES) is a Department of Veterans Affairs (VA) award with an estimated value of $152K, currently held by ELSOHLY LABORATORIES INC. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 36C24523P0029?

ELSOHLY LABORATORIES INC is the incumbent with $91K across 1 related awards in SCOUT’s public footprint. The current period of performance ends Oct 14, 2027.

When does 36C24523P0029 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 14, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C24523P0029

SCOUT Signal

August 2026

One VA health contract was 35% of civilian federal obligations in July.

Meanwhile VA's service-disabled veteran-owned contract actions fell 41.8%. The same agency, the same month, the large-vendor lane expanding while the small-business lane contracted. Figures are civilian-agency obligations through 2026-07-31; DoD FPDS for this window is labeled incomplete.

This issue is the whole civilian market. Your capture plan isn't.

Read the August 2026 issue →